What's Behind Japan Firms' Higher Approval Rates In Challenging Oncology, CNS Areas?
Alliances Play A Key Role
Despite a global tendency for lower than average success rates from Phase I to approval in the challenging oncology and CNS areas, a recent Citeline study finds top Japanese pharma firms have relatively high rates in these two categories in the US. So what are the factors driving those differences?
